Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Nevena Damjanov, MD

Nevena Damjanov, MD Physician

Director of Gastrointestinal Oncology, Abramson Cancer Center, Penn Presbyterian Medical Center Section Chief Hematology/Oncology, VA Medical Center Professor of Clinical Medicine

Dr. Damjanov is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 1996
  • Internal Medicine, 1992
  • Medical Oncology, 1995

Clinical Expertise:

  • Anal Cancer
  • Bile Duct Cancer (Cholangiocarcinoma)
  • Carcinoid Tumors
  • Colon Tumors
  • Esophageal Cancer
  • Gallbladder Cancer
  • Gastrointestinal Cancer
  • Gastrointestinal Stromal Tumors (GIST)
  • Liver Cancer
  • Neuroendocrine Tumors
  • Pancreatic Cancer
  • Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
  • Rectal Cancer
  • Small Intestine Cancer
  • Stomach Cancer (Gastric Cancer)

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Drexel University Center City Hahnemann Campus
Residency: Penn State Milton S. Hershey Medical Center
Fellowship: Hospital of the University of Pennsylvania
Fellowship: University Hospitals Case Medical Center

Memberships

American Medical Association, National American Society of Clinical Oncology, National

Hospital Affiliation

Dr. Damjanov is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.: Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck J Natl Cancer Inst 111 (5): 490-497,2019.

Wattenberg, MM, Damjanov, N., Kaplan, DE: Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience Cancer Medicine 8 (4): 1442-1446,2019.

Kim Anna Reiss, Edgar Ben-Josef, Nevena Damjanov, Maarouf Hoteit, Thomas Benjamin Karasic, Erica Carpenter, Lisa DiCicco, Luis Anna Garcia-Marcano, Rosemarie Mick, and Robert H Vonderheide: A pilot study of galunisertib (LY2157299 monohydrate) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 37 (4): 270,2019.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K: Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data Cancer 125 (3): 406-415,2019.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL.: Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma Br J Cancer 120 (2): 165-171,2019.

Michele Droz Dit Busset, Bassel F. El-Rayes, William Proctor Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Sherrie Bhoori, Monica Niger, Nicola Personeni, Fadi S. Braiteh, Sara Lonardi, Stephan Braun, Marc Engelhardt, Mikael Saulay, Brian E. Schwartz, Julia Kazakin, Walid Labib Shaib, Vincenzo Mazzaferro, and Kyriakos P. Papadopoulos: Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA). J Clin Oncol 37 (15): 2019.

Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, Hsu C, Levine M, Mondschein J, Nadolski G, Olthoff K, Reiss KA, Rosen M, Siegelman E, Metz JM, Ben-Josef E.: Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity. Am J Clin Oncol. : 2018.

Justin C. Brown, Andrew D. Rhim, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Anil K. Rustgi, Nevena Damjanov, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Babette S. Zemel, Kerry S. Courneya, Kathryn H. Schmitz: Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer PLoS One 13 (10): 2018.

Joshua Bauml, Ravi R. Vinnakota, Yeun-Hee Anna Park, Susan Elaine Bates, Antonio Tito Fojo, Charu Aggarwal, Jessica DiStefano, Christina Knepley, Eric Michael Genden, Sewanti Atul Limaye, Christine Agnes Ciunci, Juan P. Wisnivesky, Nevena Damjanov, Corey J. Langer, Roger B. Cohen, Keith Sigel: Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran’s health data J Clin Oncol 36 : (suppl; abstr 6073),2018.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 19 (5): 2018.

Academic Contact Info

Penn Presbyterian Medical Center
51 North 39th Street
103A MAB

Philadelphia, PA 19104
Phone: (215) 662-8488
Patient appointments: 800-789-7366 (PENN)

Related Links